Dimensional Fund Advisors
PLX icon

Dimensional Fund Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Dimensional Fund Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$644K Buy
296,843
+268,099
+933% +$665K ﹤0.01% 2912
2025
Q4 		$51.5K Buy
28,744
+11,716
+69% +$24K ﹤0.01% 3208
2025
Q3 		$37.5K Sell
17,028
-28,543
-63% -$46.5K ﹤0.01% 3249
2025
Q2 		$67.7K Buy
+45,571
New +$93.2K ﹤0.01% 3215

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Dimensional Fund Advisors's PLX Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Protalix BioTherapeutics (PLX) stake by 933% in Q1 2026, buying an estimated $665K and bringing the position to 296,843 shares worth $644K. The position accounts for ﹤0.01% of the portfolio, ranked #2912.

Dimensional Fund Advisors first reported a position in PLX in Q2 2025 and has held it in 4 quarters since. 100 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Dimensional Fund Advisors held 296,843 shares of Protalix BioTherapeutics worth $644K as of Q1 2026.
  • Dimensional Fund Advisors bought 268,099 Protalix BioTherapeutics shares in Q1 2026, an estimated $665K.
  • Protalix BioTherapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2912 holding.
  • Dimensional Fund Advisors first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 4 quarters since.
  • 100 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.